大麻素受体配体调节异常性肺纤维化的纤维化和炎症:一项初步研究
Sevil Köse1,2, Selin Önen3, Merve Gizer3
1Department of Plastic, Reconstructive and Aesthetic Surgery, Faculty of Medicine, Akdeniz University, Antalya, Turkiye.
Turkish journal of biology = Turk biyoloji dergisi
|January 6, 2025
概括
大麻素受体 (CBR) 激动剂通过减少炎症和纤维化,显示出治疗异常性肺纤维化 (IPF) 的潜力. 这项研究调查了CBRs.
科学领域:
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
- 细胞生物学 细胞生物学
背景情况:
- 异形性肺纤维化 (IPF) 缺乏特定的药理疗法,需要新的抗炎症策略.
- 大麻素 (CBs) 具有调节炎症和抗纤维素的特性,使其成为IPF的潜在治疗候选者.
研究的目的:
- 评估大麻素受体 (CBR) 激动剂和对抗剂的炎症调节和抗纤维作用.
- 研究CBRs在脂聚糖刺激的肺纤维细胞,上皮细胞和单细胞中的作用.
主要方法:
- 在正常和IPF肺纤维细胞,上皮细胞和单细胞中使用流细胞计检测到CBR.
- 通过ELISA量化炎症性细胞因子 (TGF-β1,IL-8,TNF-α) 和 I 型原蛋白 (ColI) 的产生.
- 通过光谱光度测量评估细胞活力.
主要成果:
- 在所有细胞类型中都存在CB1和CB2受体 (CB1R,CB2R).
- CB1R和CB2R激动剂抑制细胞增殖和调节细胞因子释放 (增加TGF-β1,TNF-α;减少IL-8).
- CB2R激动剂JWH015减少了IPF纤维细胞中的I型原体表达,表明非经典的CBR介导途径.
结论:
- 通过CBR激活进行大麻素信号传递,调节肺炎和纤维化进展.
- CBRs代表了开发IPF新型抗纤维化疗法的潜在药理学目标.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
96
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
96
NF-κB-dependent Signaling Pathway
7.2K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.2K
Inflammatory Response
1.5K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
1.5K
The JAK-STAT Signaling Pathway
8.3K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.3K
Drugs Used in Lower Respiratory Disorders: Overview
241
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
241
Antiasthma Drugs: Leukotriene Modifiers
141
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
141


